Shares of United Therapeutics Co. (NASDAQ:UTHR) have been assigned an average recommendation of “Hold” from the thirteen analysts that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $133.88.

Several research firms have recently commented on UTHR. ValuEngine downgraded United Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub downgraded United Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. Oppenheimer decreased their price objective on United Therapeutics from $160.00 to $155.00 and set an “outperform” rating on the stock in a report on Tuesday, April 9th. LADENBURG THALM/SH SH set a $124.00 price objective on United Therapeutics and gave the stock a “hold” rating in a report on Thursday, February 28th. Finally, Cowen reiterated a “hold” rating and issued a $109.00 price objective on shares of United Therapeutics in a report on Wednesday, February 27th.

Shares of UTHR traded down $1.50 during trading hours on Monday, hitting $98.84. The company had a trading volume of 424,295 shares, compared to its average volume of 378,120. The company has a market cap of $4.37 billion, a P/E ratio of 7.38 and a beta of 1.10. The company has a current ratio of 6.39, a quick ratio of 6.03 and a debt-to-equity ratio of 0.09. United Therapeutics has a 52-week low of $98.18 and a 52-week high of $130.00.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported $1.48 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.20 by ($0.72). The company had revenue of $381.40 million during the quarter, compared to analysts’ expectations of $355.81 million. United Therapeutics had a return on equity of 22.63% and a net margin of 36.20%. The firm’s quarterly revenue was down 17.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.89 EPS. Equities research analysts forecast that United Therapeutics will post 9.25 earnings per share for the current fiscal year.

In other news, Director Christopher Patusky sold 3,370 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $110.75, for a total transaction of $373,227.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Tommy G. Thompson sold 400 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $117.00, for a total transaction of $46,800.00. Following the sale, the director now directly owns 2,970 shares of the company’s stock, valued at approximately $347,490. The disclosure for this sale can be found here. Insiders have sold 46,094 shares of company stock valued at $5,284,325 over the last quarter. Company insiders own 8.20% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Financial Gravity Wealth Inc. bought a new position in United Therapeutics in the 1st quarter worth $46,000. Eqis Capital Management Inc. bought a new position in United Therapeutics in the 1st quarter worth $349,000. Unison Advisors LLC bought a new position in United Therapeutics in the 1st quarter worth $205,000. Nisa Investment Advisors LLC boosted its holdings in United Therapeutics by 19.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 21,496 shares of the biotechnology company’s stock worth $2,523,000 after buying an additional 3,561 shares during the period. Finally, Retirement Systems of Alabama boosted its holdings in United Therapeutics by 0.7% in the 1st quarter. Retirement Systems of Alabama now owns 56,915 shares of the biotechnology company’s stock worth $6,680,000 after buying an additional 403 shares during the period. 97.66% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: Why does a company issue an IPO?

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.